Search

The archetype of the self underlies the ego-complex at its root and source in the unconscious. None of these assigns to the self the role that I feel to be so essential in the syndrome. SP 50-52 sp In regard to the method of study of these processes of the archaic, unconscious psyche in psychosis, I find myself baffled as to how to set up anything like a scientific approach to the material. In this hypothesis the model is easy to visualize but difficult to understand in terms of experience; the self is seen in this case as the center of the total psychic organism, and the ego is subsumed within this totality as the center of the field of consciousness only, that is, of contents accessible to consciousness; between the two are the autonomous complexes, which are groupings of contents not accessible to ego-consciousness (Figure 1). Reconstitutive process in the psychopathology of the self1: The following paper by J.W. Perry is published with permission from the Annals of the New York Academy of the Sciences where it was first published in January 1962. The imagery I refer to is a whole class of symbolic representations of centrality and organization, of order and highest authority; I hope to demonstrate that in these we see representations of the self and processes that transform or reorganize the self in the unconscious psyche. [Extracted from the article]

Focuses on the 41st Annual Research in Medical Education RIME) Conference held in San Francisco, California from November 10-13, 2002. Agenda of the conference; Participants of the conference; Research papers presented during the conference.

Aims In order to increase the number of investigative teams and sites conducting research on pharmacological treatments for methamphetamine use disorders, the National Institute on Drug Abuse (NIDA) established an infrastructure of clinical sites in areas where methamphetamine addiction is prevalent. This multi-site infrastructure would serve to run multiple Phases II and III protocols effectively and expeditiously. Methods NIDA collaborated with investigators from the University of California at Los Angeles (UCLA) to set up the Methamphetamine Clinical Trials Group (MCTG). This paper describes the development process, as well as data from a test trial to assess the capability of research-naive sites to recruit research participants and conduct study procedures according to research protocol. Subsequent trials are also described. Results A total of 151 candidates signed consent; 65 individuals were enrolled and 35 (53.8%) completed the 12 weeks' behavioral trial. Self-reported substance use report (SUR) showed comparable use of methamphetamine across sites with the individual site means ranging from 59% (site 5) to 80% (site 3). Drug use as measured by urinalysis was greatly reduced at week 13 compared to the baseline measure; the average rate of methamphetamine-free urine samples across all participants in sites at week 13 was 53%. The highest percentage of methamphetamine-free samples was 85% at site 5; the lowest was at site 1 (40%). Addiction severity index (ASI) composite scores at baseline and protocol completion for all participants demonstrated improvement in all categories over time, except for the medical composite score. The largest composite score reduction in baseline-protocol completion was in the drug domain (0.23 versus 0.15). The changes in the ASI scores from baseline to week 13 were consistent across all five sites. Conclusions Outcomes of the behavioral trial indicated that the MCTG recruited well; collected study data accurately and reliably; and created a vehicle that can assess promising pharmacotherapies for methamphetamine addiction treatment medications. The MCTG strategy appears to be a feasible approach to increase NIDA's capacity to conduct clinical trials to evaluate potential pharmacotherapies for methamphetamine addiction. [ABSTRACT FROM AUTHOR]

Background: The preferences of autism stakeholders regarding the top priorities for future autism research are largely unknown. Objective: This study had two objectives: First, to examine what autism stakeholders think new research investments should be and the attributes of investment that they consider important, and second, to explore the feasibility, acceptability and outcomes of two prioritization exercises among autism stakeholders regarding their priorities for future research in autism. Design: This was a prospective stakeholder‐engaged iterative study consisting of best–worst scaling (BWS) and direct prioritization exercise. Setting and Participants: A national snowball sample of 219 stakeholders was included: adults with autism, caregivers, service providers and researchers. Main Outcome Measures: The main outcomes measures were attributes that participants value in future research investments, and priority research investments for future research. Results: Two hundred and nineteen participants completed the exercises, of whom 11% were adults with autism, 58% were parents/family members, 37% were service providers and 21% were researchers. Among stakeholders, the BWS exercises were easier to understand than the direct prioritization, less frequently skipped and yielded more consistent results. The proportion of children with autism affected by the research was the most important attribute for all types of stakeholders. The top three priorities among future research investments were (1) evidence on which child, family and intervention characteristics lead to the best/worst outcomes; (2) evidence on how changes in one area of a child's life are related to changes in other areas; and (3) evidence on dietary interventions. Priorities were similar for all stakeholder types. Conclusions: The values and priorities examined here provide a road map for investigators and funders to pursue autism research that matters to stakeholders. Patient or Public Contribution: Stakeholders completed a BWS and direct prioritization exercise to inform us about their priorities for future autism research. [ABSTRACT FROM AUTHOR]

Editorial. Focuses on the Fourth World Congress of Veterinary Dermatology on August 30 to September 2, 2000 in San Francisco, California. Highlights of the congress; Coverage of the themes; Integration of studies from different laboratories.

Aims: To describe the professional life of Edward H. Hon, MD, and the course of his academic career for the development of electronic fetal heart rate (FHR) monitoring. Methods: Review of archives at the Loma Linda University related to Dr Hon's early education and medical school training, his postgraduate training at Yale University, his faculty appointments at Yale University, University of Southern California and his research accomplishment related to electronic FHR monitoring. Results: Primarily, Dr Hon advanced the clinical application of the electronic FHR monitoring, particularly during labor and delivery. Dr Hon also defined significance of FHR patterns based on years of clinical studies and astute observations. Conclusion: Currently, electronic FHR monitoring, during pregnancy and labor/delivery, has a universal application. Dr Hon's research contribution on FHR monitoring, and its impact for the welfare of mother and her unborn child, is well recognized. [ABSTRACT FROM AUTHOR]

This article presents information on ninth annual convention association for advancement of Behaviour Therapy from December 12 to December 14, 1975 at Fairmont, Mark Hopkins, and Stanford Court Hotels in San Francisco, California. The convention includes symposia, research presentation, case description and advanced workshop.